United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $5.24, $0.67 better than the analyst estimate of $4.57. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $524.18 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.